USP22 and hepatocellular carcinoma: Notably, upregulation of USP22 increases ABCC1 expression and subsequently contributes to sorafenib resistance in hepatocellular carcinoma (HCC) cells, suggesting that USP22 may serve as a therapeutic target for surmounting sorafenib resistance [66].